Navigation Links
Anthera Pharmaceuticals to Present at the Citi Global Health Care Conference
Date:2/23/2012

HAYWARD, Calif., Feb. 23, 2012 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced that Paul F. Truex, Anthera's President and Chief Executive Officer, will provide a corporate presentation at the Citi Global Health Care Conference in New York, NY on Monday, February 27, 2012, at approximately 2:00 pm Eastern Time.

Citi 2012 Global Health Care Conference Presentation
Date/Time: Monday, February 27, at 2:00 pm Eastern Time
Location: The Waldorf Astoria Hotel

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. Anthera has three late stage clinical products: varespladib methyl (A-002), A-001 and blisibimod (A-623).  Varespladib methyl (A-002) and A-001 are designed to inhibit a novel enzyme target known as secretory phospholipase A2 (sPLA2). Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease. Blisibimod targets elevated levels of B-lymphocyte stimulator (BAFF) which have been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (lupus) and rheumatoid arthritis.

CONTACT: Bianca Nery of Anthera Pharmaceuticals, Inc., bnery@anthera.com or 510.856.5586.


'/>"/>
SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Anthera Pharmaceuticals Reports 2011 Fourth Quarter Financial Results and Provides Clinical Progress Update
2. Anthera Announces Fourth Quarter 2011 Financial Report and Conference Call
3. Anthera Announces Completion of Safety Review by DSMB for VISTA-16
4. Anthera Pharmaceuticals Promotes Dr. Debra Odink to Chief Technology Officer
5. Anthera Pharmaceuticals Reports 2011 Third Quarter Financial Results and Operational Update
6. Anthera Announces Last Patient Enrolled in PEARL-SC Study
7. Anthera Pharmaceuticals Announces Notice of Allowance of U.S. Patent Application Covering A-002 Plus Statin Compositions
8. Anthera Pharmaceuticals Reports 2011 Second Quarter Financial Results and Operational Update
9. Anthera Pharmaceuticals Announces Completion of Public Offering of Common Stock
10. Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
11. Anthera Pharmaceuticals Reports 2011 First Quarter Financial Results and Operational Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... , Sept. 25, 2017   Montrium ... Master File solutions, today—from the IQPC Trial Master ... , NL)—announced that EastHORN Clinical Services has ... clinical programs and TMF management. EastHORN, a leading ... eTMF platform to increase transparency to enable greater ...
(Date:9/25/2017)... 25, 2017  EpiVax, Inc., a leader in ... immune-engineering today announced the launch of EpiVax Oncology ... personalized therapeutic cancer vaccines. EpiVax has provided $500,000 ... to enabling technologies to the new precision immunotherapy ... EpiVax Oncology as Chief Executive Officer. Gad brings ...
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
Breaking Medicine Technology:
(Date:9/26/2017)... ... September 26, 2017 , ... Atmosera , a ... Management as a Service (RMaaS) to automate the deployment of websites and ... companies, e-tailers, and web development agencies who want to improve time-to-revenue with a ...
(Date:9/26/2017)... ... September 26, 2017 , ... CGL Electronic Security Inc., ... under its new umbrella, CGL Technologies, LLC. , The new CGL Technologies, LLC office ... Patitucci and Jon McCormack, both of whom have creative business development methods, who are ...
(Date:9/26/2017)... ... 26, 2017 , ... Two innovative companies are bringing to ... it is scientifically proven as well: ABAlife™. Euromed SA, a leading manufacturer of ... agreement with BioTherapeutics Inc. for patented technology for absiscic acid (ABA). , ...
(Date:9/26/2017)... (PRWEB) , ... September 26, 2017 , ... As the ... news site, https://dealfeed.sutlr.com . People are constantly trying to find tips and stories ... industry, Sutlr deal feed brings you the top trending deals. The deals are organized ...
(Date:9/26/2017)... N.J. (PRWEB) , ... September 26, 2017 , ... ... at the shore, the John R. Elliott HERO Campaign for Designated Drivers proudly ... & Golf Club. , Thirty-one local bars and restaurants took on the challenge ...
Breaking Medicine News(10 mins):